Primary Outcome Measures:
- Progression Free survival [ Time Frame: 2 years ]
Secondary Outcome Measures:
- Response [ Time Frame: after induction, 3 months post transplant, 2 months post consolidation ]
- Time To Progression [ Time Frame: 2 years ]
- Overall Survival [ Time Frame: 2 years ]
Newly diagnosed myeloma patients above the age of 65 years will be treated the following way: Bortezomib (Velcade®) based induction treatment (either Velcade Dexamethasone, Velcade Thalidomide Dexamethasone (VTD) or Velcade Cyclophosphamide Dexamethasone (VCD)). After the induction phase, for patients at least in partial remission, a collection of peripheral blood stem cells (PBSC) is done according to each center practice. High dose melphalan (140 mg/m2) followed by PBSC autologous transplantation is then performed. Three months post transplant, 2-3 cycles (similar to the initial induction phase) of consolidation are allowed.